NUVL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Nuvalent Inc (NUVL) does not currently present a strong buy opportunity for a beginner, long-term investor with $50,000-$100,000 to invest. While the company has potential in the oncology space, the lack of immediate positive catalysts, insider selling, and weak financial performance make it prudent to hold off on buying at this time.
The MACD is below 0 and negatively contracting, indicating a bearish trend. RSI is neutral at 58.236, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 103.244, with resistance at 107.209 and support at 99.279.
JPMorgan and Truist have reiterated buy/overweight ratings with price targets of $140 and $145, respectively.
Insider selling has increased significantly by 595.91% over the last month, which could indicate a lack of confidence from within the company. Additionally, there is no recent news or event-driven catalysts to support a near-term price increase. The company's financials remain weak, with no revenue and a net income loss of $122.4 million in Q3 2025.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net income loss of $122.4 million, though this was an improvement of 45.16% YoY. EPS also improved to -1.7, up 32.81% YoY. Gross margin remains at 0%.
Analysts are generally positive on Nuvalent, with JPMorgan lowering its price target slightly to $145 from $147 but maintaining an Overweight rating. Truist initiated coverage with a Buy rating and a $140 price target, citing the company's potential in oncology.
